Google (Isomorphic Labs) is developing its own medications
Isomorphic Labs — the Alphabet/DeepMind spinoff — is moving past selling AI tools to pharma and into developing its own drug candidates, with trials targeting oncology, cardiovascular disease, and neurodegenerative disease expected by end of 2026. This sits alongside Google's broader healthcare-AI push: the TxGemma open model family for drug discovery, an AI "co-scientist" for hypothesis generation, and a $1B Google Cloud/Merck AI partnership.
Why it's notable: a hyperscaler moving from "AI-for-pharma tooling" to "AI-native drug developer" is a signal of how far automation is creeping into clinical/therapeutic decision-making.